Cassiopea’s Winlevi (Clascoterone Cream) Receives the US FDA’s Approval for the Treatment of Acne Vulgaris

 Cassiopea’s Winlevi (Clascoterone Cream) Receives the US FDA’s Approval for the Treatment of Acne Vulgaris

Shots:

  • Winlevi is a first-in-class topical androgen receptor inhibitor approved by the US FDA for the treatment of acne in patients (age ≥12 yrs.) with a new mechanism of action (MOA) after ~ 40 yrs.
  • Result: Winlevi demonstrated treatment success and reductions in acne lesions and was well tolerated when used q2w (in pivotal clinical trials). Additionally, the most frequently observed local skin reaction was mild erythema
  • Winlevi (clascoterone cream 1%) is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris by limiting sebum production and inflammation. It is expected to be available in the US in early 2021

Click here ­to­ read full press release/ article | Ref: PR Newswire | Image: PR Newswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post